跳至主要内容
临床试验/CTRI/2024/11/077316
CTRI/2024/11/077316招募中不适用

A Double Blind Balanced Randomized Single Dose Two Treatment Two Sequence Two Period Two Way Crossover Oral Bioavailability Study Comparing Cocrystal Curcumin 1000 Mg Hard Capsule 4 X 250 Mg Manufactured By Wei Hai Sai Rui Space Technology Co Ltd 175 2 Dongan Road Economic And Technological Development Zone Weihai City Shandong Province, China With Doctors Best Curcumin 1000 Mg Hard Capsule 2 X 500 Mg Manufactured By 18100 Von Karman Avenue Suite 800 Irvine Ca 92612 United State In Healthy Adult Human Subjects Under Fasting Conditions

Cocrystal Health Industry Zhejiang Co Ltd1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2024年12月2日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
12
试验地点
1
主要终点
To assess the Bioavailability of Crysvital Curcumin 1000 mg Hard Capsule (2 X 500mg) Manufactured by Wei Hai Sai Rui Space Technology Co Ltd No 175 2 Dong an Road, Economic and Technological Development Zone Weihai City Shandong Province China with Doctors Best Curcumin 1000 mg Hard Capsule (2 X 500mg) Manufactured by 18100 Von Karman Avenue Suite 800 Irvine CA 92612 United State In Healthy Adult Human Subjects Under Fasting Conditions

研究概览

简要总结

At least 12 number of healthy adult human subjects will be recruited to evaluate the Bioavailability of Test product with the Reference product

In each period subjects will be housed in the clinical facility for at least 14 00 hrs pre dose to 24 00 hrs post dose A washout period of at least 07 days will be maintained between each dosing period

In each period, after an overnight fasting of at least 10 00 hrs, in the morning a single oral dose of either the test product T or reference product R will be administered as per the randomization schedule with 240 mL of drinking water at ambient temperature, to the subjects sitting in upright posture, under the supervision of the investigator or medical officer and/or trained study personnel, including the quality assurance auditors or monitor.

Blood pressure, radial pulse rate, body temperature, and wellbeing status will be enquired and recorded at pre-dose 00.00 hour within 75 minutes of before dosing and at 01 00 hrs 03 00 hrs 05 00 hrs 07 00 hrs and 12 00 hrs plus or minus 60 minutes post dose

Physical examination and vitals will be recorded before check in check out 24 00 hrs for each period and at any time if necessary.

Monitoring for adverse events will be done throughout the study period in clinical phase

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Participant and Investigator Blinded

入排标准

年龄范围
18.00 Year(s) 至 45.00 Year(s)(—)
性别
All

入选标准

  • Normal healthy adult human male and or female subjects of age between 18 to 45 years and Body Mass Index BMI ranges between 18.50 kg per m2 to 30.00 kg per m2 Subjects who have no evidence of underlying disease during screening and check in and whose screening is performed within 21 days of check in Subjects whose screening laboratory values are within normal limits are considered by the physician or principal/clinical investigator to be of no clinical significance Healthy as do cumented by the medical history including vitamins and dietary supplements physical examination including but not limited to an evaluation of the cardiovascular gastrointestinal respiratory musculoskeletal and central nervous system and vital sign assessments Generally healthy as documented by a 12 lead electrocardiogram ECG Chest X Ray and clinical laboratory assessments Willing to consume Ovo lacto vegetarian diet All subjects will be instructed to have all meals free of turmeric starting at least 07 days before period I till the end of period II and all in house meals will also be given free of turmeric Willing to comply with all requirements of this study protocol as well as instructions from the study personnel Non smokers.

排除标准

  • Evidence of allergy or known hypersensitivity to Curcumin or its inactive ingredients Subjects with hepatic encephalopathy cholestasis myasthenia pre existing liver disease alcohol abuse existing tinnitus and pre existing gallbladder disease Any major illness in the last three months or any significant ongoing chronic medical illness Renal or liver impairment Any disease or condition that might compromise the haemopoeitic gastrointestinal renal hepatic cardiovascular Musculoskeletal respiratory central nervous system or any other body system including presence of Diabetes Mellitus and Psychosis History of alcohol addiction or abuse Consumption of caffeine and /or xanthine containing products ie coffee tea chocolate caffeine containing sodas colas etc cigarettes and tobacco containing products for at least 48 00 hours prior to check in and throughout the entire study Consumption of alcohol and its products grapefruit and/or its juice and poppy containing foods within 48 00 hours prior to clinic admission and throughout the entire study Subjects who have taken any prescription medications vitamins and dietary supplements within 14 days prior to study check in and throughout the study and any over the counter medicinal products herbal medications within 07 days prior to study check in and throughout the study Subjects who have taken any unusual diet for whatever reason eg low salt for 48 00 hours prior to dosing and throughout the study Subject who had participated in any other study within the 90 days of check-in History of difficulty in swallowing History of difficulty in accessibility of veins Positive results for urine screen of drugs of abuse Marijuana THC amphetamine AMP barbiturates BAR cocaine COC benzodiazepines BZD and morphine MOR in urine prior to check-in of each period Positive results for alcohol test prior to check in of each period Any blood donation excess blood loss within 90 days of check in Ingestion of any hormonal agent at any time within 14 days prior to the start of the study check in Use of hormone replacement therapy for a period of 06 months prior to dosing Female subjects demonstrating a positive pregnancy screen Female subjects who are currently lactating Females are likely to become pregnant during the course of the study.

结局指标

主要结局

To assess the Bioavailability of Crysvital Curcumin 1000 mg Hard Capsule (2 X 500mg) Manufactured by Wei Hai Sai Rui Space Technology Co Ltd No 175 2 Dong an Road, Economic and Technological Development Zone Weihai City Shandong Province China with Doctors Best Curcumin 1000 mg Hard Capsule (2 X 500mg) Manufactured by 18100 Von Karman Avenue Suite 800 Irvine CA 92612 United State In Healthy Adult Human Subjects Under Fasting Conditions

时间窗: 15 Time Points | -12 00 hrs 00 00 hrs 00 50 hrs 01 00 hrs 02 00 hrs 02 50 hrs 03 00 hrs 03 50 hrs 04 00 hrs 04 50 hrs 05 00 hrs 06 00 hrs 08 00 hrs 10 00 hrs 24 00 hrs

次要结局

  • To monitor the safety and tolerability of test product comparing with the reference product in healthy, adult, human subjects under fasting conditions(15 Time Points)

研究者

发起方
Cocrystal Health Industry Zhejiang Co Ltd
申办方类型
Other [neutraceuticals]
责任方
Principal Investigator
主要研究者

Dr Pradeep T

Spinos Lifescience and research private limited

研究点 (1)

Loading locations...

相似试验

A Double Blind Balanced Randomized Single Dose Two... | 临床试验